Clinical trial • Not applicable • Oncology
IP-001 (novel immuno-adjuvant) for Colorectal liver metastases
Not applicable trial of IP-001 (novel immuno-adjuvant) for Colorectal liver metastases. 119 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Colorectal liver metastases
- Trial Stage
- Not applicable
Key dates
- Initial CTIS Submission Date
- 24-01-2024
- First CTIS Authorization Date
- 13-05-2024
Trial design
Not applicable trial across 1 site in Netherlands.
- Target Sample Size
- 119
Recruitment
- Planned Sample Size
- 119
- Recruitment Window Months
- 60
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 119
Netherlands
- Earliest CTIS Part Ii Submission Date
- 02-05-2024
- Latest Decision Or Authorization Date
- 07-01-2026
- Processing Time Days
- 615
- Number Of Sites
- 1
- Number Of Participants
- 119
Sites
- Site Name
- Amsterdam UMC
- Department Name
- Radiology and Nuclear Medicine
- Contact Person Name
- Martijn Meijerink
- Contact Person Email
- mr.meijerink@amsterdamumc.nl
- Number Of Participants
- 119
Sponsor
Primary sponsor
- Full Name
- Amsterdam UMC
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- IP-001 (novel immuno-adjuvant)
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- CALCIUM FOLINATE PENTAHYDRATE for Colorectal liver metastases
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer